Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis
In the present era, use of tobacco, polluted environment, poverty and aging population have become a major threat; all these factors account for a major cause of deaths by COPD. Market for COPD medication is growing with increasing prevalence rate worldwide and it has become the fourth leading cause of death. The number of people with COPD varies throughout world. Cape Town has the highest prevalence of COPD, while Hanover has the lowest prevalence.
In United States, its prevalence is high and geographically, its prevalence in the Southern part of the country is highest and the Northeastern part has the lowest prevalence rate. With increasing rate of COPD patients, the economic cost is also increasing, which leads to the highest economic cost out of all the lung diseases in United States.
Spiriva is the leading medication for the disease while rest of the medicines market is expected to decline in future with the effect of new developments and increasing competition. At present Advair has also a good hold in the market. Inhalers demand is high for COPD and there are few oral medicines available.
The present report analyses worldwide COPD market with prevalence of the disease in major parts of the world. It talks about United States and Australian market for the medication of COPD and mortality and death rates. Economic cost is also an important segment of the report in which we have discussed US and Australian markets. There are many factors driving the industry which are discussed in growth drivers. In future trends we have discussed the projected market condition, which may help in forming strategies.
The report also talks about the future outlook of the industry and its growth. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
In United States, its prevalence is high and geographically, its prevalence in the Southern part of the country is highest and the Northeastern part has the lowest prevalence rate. With increasing rate of COPD patients, the economic cost is also increasing, which leads to the highest economic cost out of all the lung diseases in United States.
Spiriva is the leading medication for the disease while rest of the medicines market is expected to decline in future with the effect of new developments and increasing competition. At present Advair has also a good hold in the market. Inhalers demand is high for COPD and there are few oral medicines available.
The present report analyses worldwide COPD market with prevalence of the disease in major parts of the world. It talks about United States and Australian market for the medication of COPD and mortality and death rates. Economic cost is also an important segment of the report in which we have discussed US and Australian markets. There are many factors driving the industry which are discussed in growth drivers. In future trends we have discussed the projected market condition, which may help in forming strategies.
The report also talks about the future outlook of the industry and its growth. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
1. COPD INDUSTRY: AN OVERVIEW
2. WORLDWIDE COPD MARKET
2.1 COPD Medication
Spiriva
Advair
Symbicort/ Pulmicort
Brovana
Xopenex
3. PREVALENCE AND MORTALITY RATE OF COPD
3.1 Prevalence in United States
3.2 Prevalence in Australia
3.3 Mortality Rate of COPD
4. ECONOMIC COST
4.1 United States
4.2 Australia
5. INDUSTRY ANALYSIS
5.1 Future Trends
Respiratory Medications Market
Prevalence Rate Continues to Grow
6. GROWTH DRIVERS
6.1 Indoor Air Pollutants
6.2 Occupational Exposure
6.3 Aging Population Leads to Surge in COPD
6.4 Smoking - A Leading cause of COPD
6.5 Air Pollution
7. COMPANY PROFILES
7.1 Glaxo Smith Kline
Overview
Business Strategies
Business and Product Expansion
Diversify Through Externalization
Re-Shape Manufacturing
7.2 AstraZeneca plc
Overview
Business Strategies
Diversified Areas of Research
Strong Presence in Emerging Markets
7.3 Merck & Co.
Overview
Business Strategies
Rolling Out a Customer-Centric Selling Model
8. MARKET OUTLOOK
8.1 Market Forecast
8.2 Forecast Methodology
8.2.1 Dependent and Independent Variables
8.2.2 Correlation Analysis
8.2.3 Regression Analysis
LIST OF TABLES
COPD Prevalence Rates by Age and Gender in Australia (2007)
Relative Risk of Mortality Due to COPD
Comparison of Costs Associated with COPD in Various Countries
COPD Cost by Type of Cost and Bearer in Australia (2008)
Value of Independent Variable (2002-08)
Correlation Table
Model Summary - Coefficient of Determination
Regression Table – Summary of Coefficients
COPD Prevalence Rates by Age and Gender in Australia (2007)
Relative Risk of Mortality Due to COPD
Comparison of Costs Associated with COPD in Various Countries
COPD Cost by Type of Cost and Bearer in Australia (2008)
Value of Independent Variable (2002-08)
Correlation Table
Model Summary - Coefficient of Determination
Regression Table – Summary of Coefficients
LIST OF CHARTS
Total Respiratory Disease Market Comparison (2001-06)
Worldwide COPD Market by Value (2003-12E)
Spiriva Market Value and Forecast (2002-11E)
Advair Sales and Forecast (2007-13E)
Flixotide Sales and Forecast (2007-13E)
Symbicort/Pulmicort Revenue and Forecast (2007-13E)
Singulair Revenue and Forecast (2007-13E)
Market Share of HFA-Based Short Acting Beta Agonists (2006-07)
Chronic Bronchitis - Percentage Distribution by Gender (2007)
Prevalence by Geographic Region (2007)
Emphysema, Percentage Distribution by Gender (2007)
Prevalence of COPD in Australia (2008)
Economic Cost of Selected Lung Diseases in US (2007)
Distribution of COPD Cost (2007)
Financial Cost of COPD by Type of Cost (2007)
Expected Respiratory Market Size and COPD Share (2010-16E)
COPD by Severity, Projected Prevalence (2008-50E)
Worldwide Aging Population (2000-10E)
Worldwide Number of Smokers (2000-10E)
Worldwide Carbon Dioxide Emissions (2004-30E)
GSK Revenues (2006-08)
AstraZeneca Revenues by Geography (2006-08)
Merck Revenues by Business Segments (2006-08)
Worldwide COPD Market Forecast (2009-10E)
Total Respiratory Disease Market Comparison (2001-06)
Worldwide COPD Market by Value (2003-12E)
Spiriva Market Value and Forecast (2002-11E)
Advair Sales and Forecast (2007-13E)
Flixotide Sales and Forecast (2007-13E)
Symbicort/Pulmicort Revenue and Forecast (2007-13E)
Singulair Revenue and Forecast (2007-13E)
Market Share of HFA-Based Short Acting Beta Agonists (2006-07)
Chronic Bronchitis - Percentage Distribution by Gender (2007)
Prevalence by Geographic Region (2007)
Emphysema, Percentage Distribution by Gender (2007)
Prevalence of COPD in Australia (2008)
Economic Cost of Selected Lung Diseases in US (2007)
Distribution of COPD Cost (2007)
Financial Cost of COPD by Type of Cost (2007)
Expected Respiratory Market Size and COPD Share (2010-16E)
COPD by Severity, Projected Prevalence (2008-50E)
Worldwide Aging Population (2000-10E)
Worldwide Number of Smokers (2000-10E)
Worldwide Carbon Dioxide Emissions (2004-30E)
GSK Revenues (2006-08)
AstraZeneca Revenues by Geography (2006-08)
Merck Revenues by Business Segments (2006-08)
Worldwide COPD Market Forecast (2009-10E)
